Collegium Pharmaceutical’s Q4 2024 Earnings Conference Call: Insights and Impacts
On February 27, 2025, Collegium Pharmaceutical, Inc. (NASDAQ:COLL) held its Fourth Quarter and Full Year 2024 Earnings Conference Call. The call was led by Danielle Jesse, Director of Investor Relations, with key executives Vikram Karnani, President & CEO, Scott Dreyer, Chief Commercial Officer, and Colleen Tupper, Chief Financial Officer in attendance. Les Sulewski from Truist Securities and David Amsellem from Piper Sandler participated as conference call participants.
Financial Highlights
During the call, Collegium Pharmaceuticals reported a net loss of $28.3 million for Q4 2024, compared to a net loss of $34.2 million in the same period the previous year. The company’s revenue for Q4 2024 was $29.5 million, a significant increase from $21.4 million in Q4 2023. For the full year 2024, Collegium reported a net loss of $111.4 million, an improvement from the net loss of $143.6 million in 2023. The company’s total revenue for 2024 was $113.8 million, up from $88.1 million in 2023.
Business Updates
CEO Vikram Karnani discussed the company’s progress in developing new products, including Xtampza ER 37.5mg, which is expected to launch in the second half of 2025. He also mentioned the successful completion of a Phase 3 study for Xtampza ER 50mg and the submission of the New Drug Application (NDA) to the Food and Drug Administration (FDA).
Impact on Investors
The positive financial results and promising business updates led to a surge in Collegium Pharmaceutical’s stock price following the earnings call. Les Sulewski from Truist Securities expressed optimism about the company’s prospects, stating, “Collegium’s Q4 results were better than expected, and the successful NDA submission for Xtampza ER 50mg is a significant milestone for the company.”
Global Impact
The development of new pain management medications, like Xtampza ER, has the potential to significantly impact the healthcare industry and the lives of millions of people suffering from chronic pain. According to the World Health Organization (WHO), an estimated 20% of adults worldwide experience chronic pain, and this number is projected to increase due to the aging population and rising rates of chronic diseases.
Conclusion
Collegium Pharmaceutical’s Q4 2024 Earnings Conference Call provided investors with encouraging financial results and promising business updates. The successful NDA submission for Xtampza ER 50mg and the upcoming launch of Xtampza ER 37.5mg are significant milestones for the company. Furthermore, the potential impact of new pain management medications on the healthcare industry and the lives of millions of chronic pain sufferers is noteworthy. As Collegium Pharmaceuticals continues to develop innovative solutions for managing chronic pain, the company’s future looks bright.
- Collegium Pharmaceuticals reported improved financial results for Q4 2024 and full year 2024.
- CEO Vikram Karnani discussed the progress of new product developments, including Xtampza ER 37.5mg and Xtampza ER 50mg.
- Positive financial results and business updates led to a surge in Collegium Pharmaceutical’s stock price.
- New pain management medications, like Xtampza ER, have the potential to significantly impact the healthcare industry and the lives of millions of chronic pain sufferers.
